Literature DB >> 11707666

Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.

G Skowron1, J C Street, E M Obee.   

Abstract

OBJECTIVE: To investigate the relationship between viral load suppression and baseline viral load as well as that between viral load suppression and baseline CD4(+) cell count.
DESIGN: Meta-analysis of published and presented studies.
METHODS: Trials of two nucleoside analogs plus nevirapine, indinavir, nelfinavir, or efavirenz as therapy for antiretroviral treatment-naive patients with HIV infection or AIDS who were followed-up for at least 6 months were included in the meta-analysis. The proportion of patients with viral loads of <200-500 copies/ml at 6 and 12 months (total number of patients, 1619 and 761, respectively) was regressed to the mean or median baseline viral load and CD4(+) cell count.
RESULTS: Thirty-six treatment arms from 30 studies were identified. Multivariate regression demonstrated a significant correlation between baseline CD4(+) cell count and virologic suppression at 6 and 12 months ( t = 2.85, p =.008; and t = 3.08, p =.010, respectively) but not between baseline viral load and virologic suppression ( t = 0.92, p =.365; and t = 1.31, p =.215, respectively). The same pattern was seen in a subanalysis of trials of nevirapine-containing therapy (CD4(+) cell count: t = 2.89, p =.014 at 6 months; viral load suppression: t = 0.84, p =.415).
CONCLUSIONS: Baseline CD4(+) cell count was a better predictor of virologic suppression induced by triple combination therapy than was baseline viral load.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707666     DOI: 10.1097/00126334-200112010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.

Authors:  Lisa M Frenkel; Yang Wang; Gerald H Learn; Jennifer L McKernan; Giovanina M Ellis; Kathleen M Mohan; Sarah E Holte; Shannon M De Vange; Diane M Pawluk; Ann J Melvin; Paul F Lewis; Laura M Heath; Ingrid A Beck; Madhumita Mahalanabis; Wilscott E Naugler; Nicole H Tobin; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  High prevalence of HIV-1 transmitted drug resistance and factors associated with time to virological failure and viral suppression in Taiwan.

Authors:  Szu-Wei Huang; Mei-Chen Shen; Wen-Hung Wang; Wei-You Li; Jen-Hsien Wang; Cheng-Yin Tseng; Po-Yu Liu; Lih-Shinn Wang; Yu-Lin Lee; Yi-Ming Arthur Chen; Chun-Yuan Lee; Po-Liang Lu; Sheng-Fan Wang
Journal:  J Antimicrob Chemother       Date:  2021-12-24       Impact factor: 5.790

4.  The importance of extended high viremics in models of HIV spread in South Africa.

Authors:  Benjamin Armbruster; Ekkehard C Beck; Mustafa Waheed
Journal:  Health Care Manag Sci       Date:  2013-06-11

5.  HIV viral load trajectories of women living with HIV in Metro Vancouver, Canada.

Authors:  Putu Duff; Kate Shannon; Melissa Braschel; Flo Ranville; Mary Kestler; Ruth Elwood Martin; Andrea Krüsi; Kathleen Deering
Journal:  Int J STD AIDS       Date:  2020-12-08       Impact factor: 1.359

6.  Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasília, Brazil During 2002-2008.

Authors:  Edson José Monteiro Bello; Amabel Fernandes Correia; José Ricardo Pio Marins; Edgar Merchan-Hamann; Luis Isamu Barros Kanzaki
Journal:  Drug Target Insights       Date:  2011-11-24

7.  Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon.

Authors:  Henry D Meriki; Kukwah A Tufon; Mbunkah H Afegenwi; Bernard A Nyindem; Pascal N Atanga; Damian N Anong; Fidelis Cho-Ngwa; Theresa Nkuo-Akenji
Journal:  Infect Dis Poverty       Date:  2014-01-30       Impact factor: 4.520

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.